sanofi aventis

Sanofi CEO Chris Viehbacher reportedly told the paper that "it's a possibility" and noted that there is no time limit in the US on takeover bids.

Sanofi ADRs are down 1.1%, or $0.38, to $34.31. Genzyme shares are down 0.1%.

Sanofi-Aventis (SNY) may extend its offer for Genzyme (GENZ) for a third time, Bloomberg reported, citing the French daily newspaper La Tribune.

Sanofi-Aventis U.S., and its U.S. Consumer Healthcare Division, Chattem, announced that the FDA has approved the Allegra family of allergy medication products for over-the-counter, or OTC, use in adults and children two years of a

A jury ruled in favor of Abbott Laboratories (ABT) and Sanofi-Aventis (SNY) in the companies' trial in which they sought to prevent Glenmark Pharmaceuticals from selling a generic version of their hypertension medicine Tarka, acco

The SAN drug Multaq, used by patients with atrial flutter and atrial fibrillation, or irregular heart rhythms to prevent strokes, has been reported to have caused liver damage in at least two female patients who were approximately

Multaq was approved in July 2009 by the FDA, and half a million prescriptions have been written for the drug ever since.

Sanofi offices in Bridgewater, N.J.

The U.S. Food and Drug Administration has recently released a warning to doctors and patients that Sanofi-Aventis' (SAN) heart drug has been linked to liver damage in several patients.

Sanofi Aventis and Genzyme - Sanofi is trying to broker a deal to buy Genzyme for $76 per share.

Google getting hit from all sides today. The search-giant's $700M acquisition of travel software company, ITA is being challenged by the U.S. government.

Coinstar gave some 4Q guidance late yesterday that was disappointing. CEO Paul Davis admits the company made a couple demand miscalculations and experienced inventory management issues within the quarter. Shares fell 24% after hou

This is what's in the news for Friday, January 14th. Reuters reports that Sanofi-aventis (SNY) will now offer about $76 a share or about $20B to hopefully win its takeover bid for Genzyme (GENZ). the Wall Street Journal report